1. Spelling, B, Taylor-Blake, B. On the exoneration of Dr. William H. Stewart: debunking an urban legend. Infectious Diseases of Poverty 2013; 2: 3.
2. Pier, GB. On the greatly exaggerated reports of the death of infectious diseases. Clin Infect Dis 2008; 47: 1113–1114.
3. Taylor, LH, Latham, SM, Woolhouse, ME. Risk factors for human disease emergence. Phil Trans R Soc Lond B Biol Sci 2001; 356(1411): 983–989.
4. Lashley, FR. Factors contributing to the occurrence of emerging infectious diseases. Biol Res Nurs 2004; 4(4): 258–267.
5. Institute of Medicine. Microbial Threats to Health: Emergence, Detection and Response. Washington, DC, National Academies Press, 2003.
9. Institute of Medicine. Biological Threats and Terrorism: Assessing the Science and Response Capabilities. Washington, DC, National Academies Press, 2002.
10. Naylor, CD, Chantler, C, Griffiths, S. Learning from SARS in Hong Kong and Toronto. JAMA 2004; 291(20): 2483–2487.
11. Enserink, M. SARS in China. China's missed dance. Science 2003; 301(5631): 294–296.
12. U.S. Centers for Disease Control and Prevention (CDC). Update: severe acute respiratory syndrome – Toronto, Canada. MMWR 2003; 52(23): 547–550.
13. Osterholm, MT. How to vaccinate 30000 people in three days: realities of outbreak management. Pub Health Report 2001; 116 (Suppl. 2): 74–78.
14. Ferguson, NM, Cummings, DAT, Fraser, C, Cajka, JC, Cooley, PC, Burke, DS. Strategies for mitigating an influenza pandemic. Nature 2006; 442(7101): 448–452.
15. Barbisch, D, Koenig, KL,Shih, F-Y. Is There a Case for Quarantine? Perspectives from SARS to Ebola. Disaster Medicine and Public Health Preparedness, 2015. DOI: 10.1017/dmp.2015.38.
16. CDC. Severe acute respiratory syndrome – Singapore, 2003. MMWR 2003; 52(18): 405–411.
18. Stratton, SJ. Cholera in Haiti: redefining emergency public health philosophy. Prehosp and Disaster Med 2013; 28(3): 195–196.
19. Braden, CR, Dowell, SF, Jernigan, DB, Hughes, JM. Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome. Emerg Infect Dis 2013; 19(6): 864–869.
20. Berg, R. Salmonella Saint Paul: what went wrong? J Environ Health 2008; 71(5): 50–52.
21. Spanish farmers paid a price for Europe's E. coli O104 outbreak. Food Safety News. July 9, 2012.
22. Koenig, KL. Identify-Isolate-Inform: A modified tool for initial detection and management of Middle East Respiratory Syndrome patients in the emergency department. West JEM 2015. http://escholarship.org/uc/item/3k27v8g1 (Accessed August 8, 2015).
23. Peters, CJ, LeDuc, JW. An introduction to Ebola: the virus and the disease. J Infect Dis 1999; 179(Suppl 1): ix–xvi.
24. McDonald, LC, Simor, AE, Su, I-J, et al. SARS in healthcare facilities, Toronto and Taiwan. Emerg Infect Dis 2004; 10(5): 777–781.
25. Assiri, A, McGeer, A, Perl, TM, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 2013; 369(5): 407–416.
26. Qureshi, K, Gershon, RRM, Sherman, MF, et al. Health care workers’ ability and willingness to report to duty during catastrophic disasters. J Urban Health Bull NY Acad Med 2005; 82(3): 378–388.
27. Balicer, RD, Barnett, DJ, Thompson, CB, et al. Characterizing hospital workers’ willingness to report to duty in an influenza pandemic through threat- and efficacy-based assessment. BMC Public Health 2010; 10: 436.
28. Devnani, M. Factors associated with the willingness of health care personnel to work during an influenza public health emergency: an integrative review. Prehosp Disaster Med 2012; 27(6): 551–566.
30. Shepard, CW, Soriano-Gabarro, M, Zell, ER, et al. Antimicrobial postexposure for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 8(10): 1124–1132.
31. Date, KA, Vicari, A, Hyde, TB, et al. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 12011; 7(11): 2105–2112.
32. Centers for Disease Control and Prevention. Healthcare Infection Control Practices Advisory Committee (HICPAC). 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings. http://www.cdc.gov/hicpac/2007ip/2007isolationprecautions.html (Accessed August 10, 2015).
34. Hawryluck, L, Gold, WL, Robinson, S, Pogorski, S, Galea, S, Styra, R. SARS control and psychological effects of quarantine, Toronto, Canada. Emerg Infect Dis 2004; 10(7): 1206–1212.
35. O'Toole, T, Mair, M, Inglesby, TV. Shining light on “Dark Winter.” Clin Infect Dis 2002; 34(7): 972–983.
36. Wynia, MK, Gostin, LO. Ethical challenges in preparing for bioterrorism: barriers within the healthcare system. Am J Pub Health 2004; 94(7): 1096–1102.
38. Beecher, DJ. Forensic application of microbiological culture analysis to identify mail intentionally contaminated with Bacillus anthracis spores. Appl Environ Microbiol 2006; 72(8): 5304–5310.
42. Katz, RL, Fernandez, JA, McNabb, SJN. Disease surveillance, capacity building and implementation of the International Health Regulations (IHR). BMC Public Health 2010; 10(Suppl): S1.
45. Arnold, JL, Dembry, L-M, Tsai, M-C, et al. Recommended modifications and applications of the hospital emergency incident command system for hospital emergency management. Preshosp Disaster Med 2005; 20(5): 290–300.
47. Rubinson, L, Nuzzo, JB, Talmor, DS, O'Toole, T, Kramer, BR, Inglesby, TV, for the Working Group on Emergency Mass Critical Care. Augmentation of hospital critical care capacity after bioterrorist attacks or epidemics: recommendations of the Working Group on Emergency Mass Critical Care. Crit Care Med 2005; 33(10): 2393–2403.
48. Fumento, MJ. The threat of an avian flu pandemic is over-hyped. Virtual Mentor 2006; 8(4): 265–270.
49. U.S. General Accounting Office. West Nile virus outbreak. Lessons for public health preparedness. GAO/HEHS-00–180. Washington, DC, General Accounting Office, 2000.
50. Chan, PKS. Outbreak of avian influenza (H5N1) virus infection in Hong Kong in 1997. Clin Infect Dis 2002; 34(Suppl 2): S58–S64.
51. Chua, KB. Nipah virus outbreak in Malaysia. J Clin Virol 2003; 26(3): 265–275.
52. Ksiazek, TG, Erdman, D, Goldsmith, CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348(20): 1953–1966.
53. Spellberg, B, Powers, JH, Brass, EP, Miller, LG, Edwards, JE. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38(9): 1279–1286.
54. Bassetti, M, Merelli, M, Temperoni, C, Astilean, A. New antibiotics for bad bugs: where are we? Annals Clin Microbiol Antimicrobials 2013; 12: 22.
55. Stockman, LJ, Bellamy, R, Garner, P. SARS: systematic review of treatment effects. PLoS Med 2006; 3(9): e343.
57. American Society for Microbiology. ASM comments on the Biodefense and Pandemic Vaccine and Drug Development Act of 2005. November 4, 2005. www.asm.org/Policy/index.asp?bid=38723 (Accessed November 12, 2008).
60. Institute of Medicine. Learning from SARS: Preparing for the Next Disease Outbreak. Washington, DC, National Academies Press, 2004.
64. Svoboda, T, Henry, B, Shulman, L, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med. 2004; 350(23): 2351–2361.
65. CDC. Health Alert Network Update: Multistate outbreak of fungal infections among persons who received injections with contaminated medication. December 12, 2012. http://emergency.cdc.gov/HAN/han00338.asp (Accessed September 20, 2013).
66. U.S. General Accounting Office. Influenza pandemic. Challenges in preparedness and response. GAO-05–863T. Washington, DC, General Accounting Office, 2005.
67. Gautret, P, Benkouiten, S, Salaheddine, I, et al. Hajj pilgrims’ knowledge about Middle East respiratory syndrome coronavirus, August to September 2013. Eurosurveillance October 10, 2013;18(41).
68. Bardi, J. Aftermath of a hypothetical smallpox disaster. Emerg Infect Dis 1999; 5(4): 547–551.
70. Hick, JL, O'Laughlin, DT. Concept of operations for triage of mechanical ventilation in an epidemic. Acad Emerg Med 2006; 13(2): 223–229.
71. Burkle, FM. Population-based triage management in response to surge-capacity requirements during a large-scale bioevent disaster. Acad Emerg Med 2006; 13(11): 1118–1129.
75. Lobitz, B, Beck, L, Huq, A, et al. Climate and infectious disease: use of remote sensing for detection of Vibrio cholerae by indirect measurement. Proc Natl Acad Sci USA 2000; 97(4): 1438–1443.
76. Stein, ML, Rudge, JW, Coker, R, et al. Development of a resource modeling tool to support decision makers in pandemic influenza preparedness: The AsiaFluCap Simulator. BMC Public Health 2012; 12: 870.
77. Becker, NG, Wang, D. Can antiviral drugs contain pandemic influenza transmission? PLoS One 2011; 6(3): e17764.
78. Araz, OM, Galvani, A, Meyers, LA. Geographic prioritization of distributing pandemic influenza vaccines. Health Care Manag Sci 2012; 15(3): 175–87.
79. Smith, RD, Keogh-Brown, MR. Macroeconomic impact of pandemic influenza and associated policies in Thailand, South Africa and Uganda. Influenza Other Respi Viruses 2013; 7 (Suppl. 2): 64–71.
80. Maharaj, S, Kleczkowski, A. Controlling epidemic spread by social distancing: do it well or not at all. BMC Public Health 2012; 12: 679.
81. Asch, SM, Stoto, M, Mendes, M, et al. A review of instruments assessing public health preparedness. Pub Health Report 2005; 120(5): 532–542.
82. Amadio, JB. Bioterrorism preparedness funds well used at the local level. Am J Pub Health 2004; 95(3): 373–374.
83. Cohen, HW, Gould, RM, Sidel, VW. The pitfalls of bioterrorism preparedness: the anthrax and smallpox experiences. Am J Pub Health 2004; 94(10): 1667–1671.
84. Wortley, PM, Schwartz, B, Levy, PS, Quick, LM, Evans, B, Burke, B. Healthcare workers who elected not to receive smallpox vaccination. Am J Prevent Med 2006; 30(3): 258–265.
85. Institute of Medicine. Ending the War Metaphor: The Changing Agenda for Unraveling the Host-Microbe Relationship. Washington, DC, National Academies Press, 2006.
86. King, DA, Peckham, C, Waage, JK, Brownlie, J, Woolhouse, ME. Epidemiology. Infectious diseases: preparing for the future. Science. 2006; 313(5792): 1392–1393.
87. Pulendran, B, Ahmed, R. Translating innate immunity into immunological memory: implications for vaccine development. Cell 2006; 124(4): 849–863.
88. Liu, MA, Wahren, B, Karlsson, Hedestam GB. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 2006; 17(11): 1051–1061.
89. Koff, WC, Burton, DR, Johnson, PR, Walker, BD, et al. Accelerating next-generation vaccine development for global disease prevention. Science 2013; 340(6136): 1232910.
90. Infectious Diseases Society of America. The 10 x ’20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020. Clin Infect Dis 2010; 50(8): 1081–1083.
91. Scott, A. Europe invests $550 million into drug discovery and antibiotic development. Chemical & Engineering News 2013; 91(7): 8.
92. Boucher, HW, Talbot, GH, Benjamin, DK., et al. 10 x ’20 progress – development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin Infect Dis 2013: 56(12): 1685–1694.
93. So, AD, Ruiz-Esparza, Q, Gupta, N, Cars, O. 3Rs for innovating novel antibiotics: sharing resources, risks, and rewards. BMJ 2012; 344: e1782.